Mani, Inc. (TYO:7730)
Japan · Delayed Price · Currency is JPY 1,431.50
+3.00 (0.21%)
Oct 10, 2025, 3:30 PM JST
Mani, Inc. Revenue
In the fiscal year ending August 31, 2025, Mani, Inc. had annual revenue of 29.97B JPY with 5.10% growth. Mani, Inc. had revenue of 7.58B in the quarter ending August 31, 2025, with 9.79% growth.
Revenue
29.97B
Revenue Growth
+5.10%
P/S Ratio
4.71
Revenue / Employee
7.21M
Employees
4,154
Market Cap
141.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 29.97B | 1.46B | 5.10% |
| Aug 31, 2024 | 28.51B | 4.03B | 16.44% |
| Aug 31, 2023 | 24.49B | 4.07B | 19.95% |
| Aug 31, 2022 | 20.42B | 3.23B | 18.77% |
| Aug 31, 2021 | 17.19B | 1.99B | 13.09% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.21B |
| Daiichi Sankyo Company | 1,924.68B |
| HOYA Corporation | 876.09B |
| Takeda Pharmaceutical Company | 4,480.25B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |